Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.

Entospletinib effectively prevents eye and skin GVHD in mice.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Iressa often causes skin issues like acne and dryness in lung cancer patients.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Photodynamic therapy improved skin issues from sorafenib when other treatments failed.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.

MK-5108 is safe and shows potential against tumors, especially alone.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.

Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Tadalafil and Finasteride may help treat aggressive melanoma.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.